Compare · AZN vs KROS
AZN vs KROS
Side-by-side comparison of AstraZeneca PLC (AZN) and Keros Therapeutics Inc. (KROS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and KROS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $576.71B, about 2829.0x KROS ($203.9M).
- AZN has been more active in the news (21 items in the past 4 weeks vs 10 for KROS).
- AZN has more recent analyst coverage (25 ratings vs 22 for KROS).
- Company
- AstraZeneca PLC
- Keros Therapeutics Inc.
- Price
- $182.27-2.01%
- $10.05-2.33%
- Market cap
- $576.71B
- $203.9M
- 1M return
- -
- -13.51%
- 1Y return
- -
- -28.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 21
- 10
- Recent ratings
- 25
- 22
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Keros Therapeutics Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest KROS
- Director Seth Alpna was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)
- Director Seth Alpna sold $28,140 worth of shares (2,625 units at $10.72) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 9,767 units (SEC Form 4)
- Director Gray Mary Ann was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)
- Director Farzan Nima was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)
- Director Bienaime Jean Jacques was granted 7,142 shares, increasing direct ownership by 76% to 16,592 units (SEC Form 4)
- Director Knowles Julius was granted 7,142 shares, increasing direct ownership by 111% to 13,583 units (SEC Form 4)
- Keros Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Keros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
- Director Bienaime Jean Jacques bought $10,580 worth of shares (1,000 units at $10.58), increasing direct ownership by 12% to 9,450 units (SEC Form 4)